Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126748771 | 12674877 | 1 | I | 201102 | 20160809 | 20160823 | 20160823 | EXP | CN-CIPLA LTD.-2016CN17423 | CIPLA | 0.00 | Y | 0.00000 | 20160823 | OT | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126748771 | 12674877 | 1 | SS | Epirubicin | EPIRUBICIN | 1 | Unknown | 60 MG/M2, UNK ON DAY 1 | U | U | 0 | 60 | MG/M**2 | ||||||
| 126748771 | 12674877 | 2 | PS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | 1 G/M2 ON DAYS 1 AND 8 | U | U | 78759 | ||||||||
| 126748771 | 12674877 | 3 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Unknown | 750 MG/M2, UNK ON DAY 1 | U | U | 0 | 750 | MG/M**2 | ||||||
| 126748771 | 12674877 | 4 | SS | Vincristine | VINCRISTINE | 1 | Unknown | 1.4 MG/M2, ON DAY 1 | U | U | 0 | 1.4 | MG/M**2 | ||||||
| 126748771 | 12674877 | 5 | SS | DACARBAZINE. | DACARBAZINE | 1 | Unknown | 250 MG/M2, FROM DAY 1 TO 5, REPEATED EVERY THREE WEEKS | U | U | 0 | 250 | MG/M**2 | ||||||
| 126748771 | 12674877 | 6 | SS | DOCETAXEL. | DOCETAXEL | 1 | Unknown | 75 MG/M2, ON DAY 1, REPEATED EVERY THREE WEEKS. | U | U | 0 | 75 | MG/M**2 | ||||||
| 126748771 | 12674877 | 7 | SS | DOCETAXEL. | DOCETAXEL | 1 | Unknown | 60 MG/M2, ON DAY 1 | U | U | 0 | 60 | MG/M**2 | ||||||
| 126748771 | 12674877 | 8 | SS | CISPLATIN. | CISPLATIN | 1 | 75 MG/M2, ON DAY 1, REPEATED EVERY 3 WEEKS | U | U | 0 | 75 | MG/M**2 | |||||||
| 126748771 | 12674877 | 9 | SS | CISPLATIN. | CISPLATIN | 1 | 30 MG/M2, ON DAY 1-2 | U | U | 0 | 30 | MG/M**2 | |||||||
| 126748771 | 12674877 | 10 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | 75 MG/M2, ON DAY 1 AND 15 | U | U | 0 | 75 | MG/M**2 | ||||||
| 126748771 | 12674877 | 11 | SS | Endostatin | ENDOSTATIN | 1 | Unknown | 15 MG, ON DAYS 1 TO 14, REPEATED EVERY THREE WEEKS | U | U | 0 | 15 | MG | ||||||
| 126748771 | 12674877 | 12 | C | Thalidomide | THALIDOMIDE | 1 | Oral | 100 MG, THROUGHOUT THE TREATMENT PROCESS AND CHEMOTHERAPY INTERVALS | U | U | 0 | 100 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126748771 | 12674877 | 1 | Angiosarcoma metastatic |
| 126748771 | 12674877 | 2 | Metastases to liver |
| 126748771 | 12674877 | 3 | Angiosarcoma metastatic |
| 126748771 | 12674877 | 4 | Angiosarcoma metastatic |
| 126748771 | 12674877 | 5 | Angiosarcoma metastatic |
| 126748771 | 12674877 | 6 | Angiosarcoma |
| 126748771 | 12674877 | 8 | Angiosarcoma |
| 126748771 | 12674877 | 9 | Metastases to liver |
| 126748771 | 12674877 | 11 | Metastases to liver |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126748771 | 12674877 | OT |
| 126748771 | 12674877 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126748771 | 12674877 | Bone marrow failure | |
| 126748771 | 12674877 | Death | |
| 126748771 | 12674877 | Disease progression | |
| 126748771 | 12674877 | Disease recurrence | |
| 126748771 | 12674877 | Hepatic function abnormal | |
| 126748771 | 12674877 | Leukopenia | |
| 126748771 | 12674877 | Nausea |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |